Although the present pilot study focused on the effect of pemafibrate in patients with both NAFLD and T2DM who were refractory to SGLT2 inhibitor therapy, the results suggest that the combination of pemafibrate and SGLT2 inhibitor is useful for patients with NAFLD who suffer from both T2DM and dyslipidemia. The gene discussed is SLC5A2; the disease is metabolic syndrome.